Advanced Breast Cancer Clinical Trial
Official title:
A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
| Verified date | February 2017 |
| Source | Chinese Academy of Medical Sciences |
| Contact | Binghe Xu |
| syhiir[@]126.com | |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
To study the epidemiological trends and characteristics for advanced breast cancer patients, to analyze these trends and report the results
| Status | Recruiting |
| Enrollment | 4200 |
| Est. completion date | December 2017 |
| Est. primary completion date | April 2017 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years to 99 Years |
| Eligibility |
Inclusion Criteria: - diagnosed as advanced breast cancer during Jan1st,2012-Dec31st,2014 - complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases. Exclusion Criteria: - no available medical record |
| Country | Name | City | State |
|---|---|---|---|
| China | The 307th Hospital of Military Medical Sciences | Beijing | |
| China | Sichuan Cancer Hospital and Institute | Chengdu | |
| China | The First Affliated Hospital of Chongqing Medical University | Chongqing | |
| China | FuZhou General Hospital of National Miltary Command | Fuzhou | |
| China | Sun Yat-Sen University Cancer Center | Guangzhou | |
| China | Harbin Medical University Cancer Hospital | Harbin | |
| China | Henan Cancer Hospital | Henan | |
| China | Hunan Cancer Hospital | Hunan | |
| China | Jiangsu Provinces hospital | Jiangsu | |
| China | Tumor Hospital of Yunnan Province | Kunming | |
| China | Liaoning Cancer Hospital, Zhejiang Cancer Hospital | Liaoning | |
| China | General Hospital of NingXia Medical University | Ningxia | |
| China | Fudan University Shanghai Cancer Center | Shanghai | |
| China | The First Hospital of China Medical University | Shenyang | |
| China | Tianjin Medical University Cancer Institute & Hospital | Tianjin | |
| China | Wuhan Union Hospital | Wuhan | |
| China | The First Hospital of Xi'an Jiaotong University | Xi'an | |
| China | Xinjiang Medical University Cancer Hospital | Xinjiang | |
| China | FuJian Provincial Cancer Hospital | Zhengzhou |
| Lead Sponsor | Collaborator |
|---|---|
| Chinese Academy of Medical Sciences |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Survival status at 3 years | percentage of patients still alive at 3 years | 3 years | |
| Secondary | PFS | Progression-free survival of first line therapy | 3 years | |
| Secondary | Survival status at 5 years | percentage of patients still alive at 5 years | 3 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04653740 -
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
|
N/A | |
| Completed |
NCT02091960 -
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05156619 -
Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
|
||
| Recruiting |
NCT05173103 -
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
|
||
| Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
| Completed |
NCT00754325 -
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
|
Phase 2 | |
| Recruiting |
NCT04953377 -
PFMT Educational Intervention for Patients With Advancer Breast Cancer
|
N/A | |
| Completed |
NCT03240224 -
Bioinformation Therapy for Breast Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06193525 -
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
|
Phase 2 | |
| Completed |
NCT03312738 -
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
|
Phase 2 | |
| Active, not recruiting |
NCT05063786 -
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
|
Phase 3 | |
| Recruiting |
NCT05655598 -
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02499146 -
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
| Completed |
NCT04408118 -
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
|
Phase 2 | |
| Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03205761 -
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT04316169 -
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
|
Phase 1 | |
| Completed |
NCT00546104 -
Phase II Dasatinib Study in Advanced Breast Cancer
|
Phase 2 |